In the well-known HER2 breast tumor subtype, the driving characteristic of the subtype is the HER2 oncogene activation through concordant DNA amplification and mRNA overexpression of genes within the HER2 amplicon (Supplementary Figure S1D). This evidence concerns the gene ERBB2 and breast neoplasm.